
Aerie Pharmaceuticals AERI
Quartalsbericht 2022-Q3
hinzugefügt 23.12.2023
Aerie Pharmaceuticals Anteile 2011-2025 | AERI
Anteile Jährlich Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 46.3 M | 45.9 M | 45.4 M | 41.7 M | 35.3 M | 29.1 M | 25.8 M | 24.1 M | 4.96 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 46.3 M | 4.96 M | 33.2 M |
Anteile Vierteljährlich Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 47.8 M | 47.6 M | 47.5 M | 48.4 M | 46.3 M | 46.2 M | 46.1 M | 46.8 M | 45.9 M | 45.9 M | 45.8 M | 46.5 M | 45.4 M | 45.4 M | 45.3 M | 45.5 M | 43.7 M | 39.2 M | 38.6 M | 36.9 M | 36.2 M | 34.8 M | 33.8 M | 33.5 M | 29.4 M | 26.8 M | 26.7 M | 26.5 M | 26.1 M | 25.8 M | 24.6 M | 24 M | 24.3 M | 23.9 M | 23.7 M | 23.3 M | 1.01 M | 982 K | 965 K | 965 K | 965 K | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 48.4 M | 965 K | 32.9 M |
Anteile anderer Aktien in der Arzneimittelhersteller
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
108 M | $ 1.7 | 50.0 % | $ 183 M | ||
|
Cronos Group
CRON
|
350 M | $ 3.24 | 13.51 % | $ 1.69 B | ||
|
Assertio Holdings
ASRT
|
71 M | $ 0.77 | -1.79 % | $ 54.7 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
169 M | $ 5.36 | 17.8 % | $ 86.3 M | ||
|
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
51.2 M | $ 11.46 | -2.22 % | $ 587 M | ||
|
Evoke Pharma
EVOK
|
3.34 M | $ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | $ 21.38 | -0.05 % | $ 2.03 B | ||
|
Evolus
EOLS
|
62 M | $ 6.99 | 1.09 % | $ 433 M | ||
|
Harrow Health
HROW
|
32.6 M | $ 47.18 | -7.67 % | $ 1.54 B | ||
|
China Pharma Holdings
CPHI
|
17.5 M | $ 1.67 | 11.33 % | $ 29.2 M | ||
|
cbdMD
YCBD
|
4.31 M | $ 1.18 | 87.31 % | $ 5.09 M | ||
|
Bausch Health Companies
BHC
|
365 M | $ 6.95 | -0.93 % | $ 2.54 B | ||
|
OrganiGram Holdings
OGI
|
256 M | $ 1.88 | 14.72 % | $ 402 M | ||
|
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 2.61 | 4.99 % | $ 36.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
132 M | $ 4.83 | 1.15 % | $ 636 M | ||
|
Pacira BioSciences
PCRX
|
46.2 M | $ 26.28 | 2.14 % | $ 1.22 B | ||
|
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
30.1 M | $ 4.12 | -1.67 % | $ 124 M | ||
|
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
137 M | $ 13.13 | -2.23 % | $ 1.8 B | ||
|
ProPhase Labs
PRPH
|
15.8 M | $ 0.12 | -15.26 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
23.3 M | $ 0.93 | -2.37 % | $ 21.7 M | ||
|
Sundial Growers
SNDL
|
1.86 M | $ 2.19 | 24.01 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
47.9 M | $ 0.64 | -0.02 % | $ 30.6 M | ||
|
Solid Biosciences
SLDB
|
40.8 M | $ 5.85 | -0.34 % | $ 239 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 3.59 | -3.37 % | $ 4.46 M | ||
|
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
618 M | $ 11.86 | 40.68 % | $ 7.33 B | ||
|
TherapeuticsMD
TXMD
|
10.4 M | $ 1.79 | -2.72 % | $ 18.7 M | ||
|
Zomedica Corp.
ZOM
|
980 M | - | -0.21 % | $ 98 M | ||
|
Veru
VERU
|
135 M | $ 2.45 | -4.3 % | $ 330 M | ||
|
Viatris
VTRS
|
1.21 B | $ 11.63 | 0.3 % | $ 14.1 B |